Your session is about to expire
← Back to Search
OCT Angiography for Retinopathy (OCTA-RVD Trial)
OCTA-RVD Trial Summary
This trial will help better define when someone with retinal vascular disease is progressing or regressing so that treatment can be more accurately given.
OCTA-RVD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OCTA-RVD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Controls
- Group 2: Diabetics with and without Diabetic Retinopathy Only
- Group 3: Diabetics w/ or w/o Diabetic Retinopathy & Hypertension
- Group 4: Hypertension Only
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the trial include minors within its parameters?
"As per the eligibility requirements, participants between 18 and 99 years old are qualified to take part in this clinical trial. There are an additional 13 trials specifically for minors and 219 studies available for adults over 65."
What type of patient can best benefit from this trial?
"The prerequisites for entering this clinical trial are that prospective patients must possess diabetic retinopathy and be aged between 18 to 99 years old. The goal of the research is to recruit 1050 individuals."
Are there any vacancies available in the experiment?
"This medical research programme is enrolling participants, as per the latest updates on clinicaltrials.gov. It was first announced in October 2019 and was revised last August 2022."
What is the cap on participant numbers for this experiment?
"Yes, the details listed on clinicaltrials.gov verify that this research study is actively enrolling participants. This trial was initially posted in October 2019 and edited for the last time in August 2022. It requires 1050 individuals from 2 medical facilities to participate."
Share this study with friends
Copy Link
Messenger